OCGN: ocugen.com Debt to Equity

Ocugen, Inc. (OCGN) is penetrating the niche of inhalation drugs and vision therapy, driving demand through strategic partnerships. The high scalability of its intellectual property will ensure low costs under a monopoly distribution model. This chart of the market trend for the debt-to-equity ratio is fixed at 0.00. Meanwhile, the business relies on external outsourcing, having fully delegated production and testing to third-party contractors without maintaining its own facilities.

The debt-to-equity ratio determines the extent of a business's dependence on external creditors relative to its own funds. The trend of the total credit load to capital reflects the balance between financial stability and expansion. This metric is calculated as the ratio of total liabilities to net asset value. For Ocugen, Inc. (OCGN), this is a critical marker given the costs associated with vaccine development. The constant search for financing amid regulatory risks makes this indicator key to assessing solvency.